Bicara Therapeutics

Today, we are thrilled to announce the completion of our oversubscribed $165M Series C financing with support from new and existing leading healthcare investors, who share in Bicara’s vision for our lead clinical program, BCA101, to make a meaningful difference for patients. Following our Phase 1/1b data presentations at key medical meetings in 2023, momentum at Bicara is greater than ever and this financing is a testament to our progress as we work to provide first-in-class therapies to patients with #headandneckcancer.    We also are excited to welcome Carolyn Ng, Ph.D., to our board of directors. Her shared commitment to our mission will play a pivotal role in our growth and development. Read more in the release here: https://lnkd.in/ey_zX4FA

Today, we are at the 3rd Hawaii Summit on Thoracic Malignancies, and excited to share updated interim data from our ongoing, open-label Phase 1/1b dose expansion study of ficerafusp alfa (BCA101) in 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. #HNSCC is one of the most common cancers globally with a rising incidence, and this approach may become a new chemotherapy-free standard of care treatment for patients in need. Learn more in the release here: https://lnkd.in/e4PMdm6C

The two subtypes of Head and Neck Cancer (HNC) are distinctly associated with smoking/drinking and/or human papillomavirus (HPV) infection, and are often preventable. If diagnosed early, chances for survival can more than double. Screenings typically take less than 10 minutes. Get screened for HPV and HNC this #HeadandNeckCancerAwarenessMonth!

The highest burden of head and neck cancer calls not only on patients, but also caregivers. At Bicara, our commitment to patients and their caregivers is unwavering. We believe our research for BCA101 has the potential to improve and extend the lives of people with head and neck squamous cell carcinoma and other solid tumor #cancer types. Learn about our commitment to advance meaningful new therapies here: https://lnkd.in/gp-x_kx

Head and neck squamous cell carcinomas (HNSCC) are one of the most common and debilitating cancers worldwide. But did you know men are 2x more likely to be diagnosed with head and neck cancers than women? Learn more about reducing your risk here: https://lnkd.in/eeZuNh7

Head and Neck Cancers are also known as head and neck squamous cell carcinomas (HNSCC) and most commonly develop within the oral cavity, pharynx, and larynx. With cases of #HNSCC on the rise, our team is dedicated to developing first-in-class #cancer therapeutics to both improve and extend the lives of those impacted by solid tumor cancers. To learn more about our #research, visit the link here: https://lnkd.in/eW-xPrbW

Cancers of the head and neck are classified as cancers found in a patient’s larynx, throat, lips, mouth, nose, and/or salivary glands. These cancers are the 6th most common worldwide. At Bicara, we are focused on developing potential treatments for these difficult to treat tumors. To learn more about our commitment to #headandneckcancers and lessening the burden of these diagnoses, visit our website. https://lnkd.in/gp-x_kx

Meet David Raben, M.D., our Chief Medical Officer at Bicara. With 25+ years in #oncology, his leadership propels our drug development forward, crafting impactful therapies for #cancer patients.

We’re delighted to share that Jeltje Schulten, MD, MBA, and Rita Dalal, MBBS, MPH, have both joined Bicara as SVP, Head of Global Medical and Clinical Affairs and VP of Clinical Development, respectively.   Their expertise are invaluable to Bicara as we continue to bring BCA101 forward to deliver better treatment solutions for cancer patients. Welcome, Jeltje and Rita!   Learn about our new hires: https://lnkd.in/e_sTcKeJ

At Bicara, we value inclusivity in all aspects of our company. With this year’s International Women’s Day theme being #inspireinclusion, we have asked the women on our leadership team to speak on their experience and how to empower other women. Read their quotes below! #IWD2024